T1	DISO 218 221	VHC
#1	AnnotatorNotes T1	C0019196; Hepatitis C; Disease or Syndrome
T2	PROC 67 95	evaluar eficacia y seguridad
T3	CHEM 123 132	Ritonavir
#2	AnnotatorNotes T3	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T4	DISO 168 216	infección crónica por el virus de la Hepatitis C
#3	AnnotatorNotes T4	C4736230; chronic hepatitis C due to hepatitis C virus genotype 1a; Disease or Syndrome | C4736234; chronic hepatitis C due to hepatitis C virus genotype 4; Disease or Syndrome
T5	DISO 251 270	insuficiencia renal
#4	AnnotatorNotes T5	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T6	DISO 279 298	nefropatía terminal
#5	AnnotatorNotes T6	C0022661; Kidney Failure, Chronic; Disease or Syndrome
T7	CHEM 99 109	Ombitasvir
#6	AnnotatorNotes T7	C3852670; ombitasvir; Organic Chemical · Pharmacologic Substance
T8	DISO 332 365	Infección Cronica por Hepatitis C
T9	DISO 395 419	Infección crónica de VHC
T10	DISO 476 489	infección VHC
#7	AnnotatorNotes T10	C0019196; Hepatitis C; Disease or Syndrome
T11	PHYS 756 771	posmenopáusicas
#8	AnnotatorNotes T11	C0206159; Postmenopause; Organism Function
T12	PROC 547 568	tratamiento antiviral
#9	AnnotatorNotes T12	C2363964; Antiviral treatment; Therapeutic or Preventive Procedure
T13	PROC 698 702	MDRD
#10	AnnotatorNotes T13	C1980036; Creatinine-based formula (MDRD); Laboratory Procedure
T14	DISO 577 602	infección por hepatitis C
T15	PROC 607 643	Tasa estimada de filtrado glomerular
#11	AnnotatorNotes T15	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T16	PROC 645 649	eGFR
#12	AnnotatorNotes T16	C0C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T17	DISO 800 809	estériles
#13	AnnotatorNotes T17	C0021359; Infertility; Pathologic Function | C0917730; Female sterility; Finding | C4074771; Sterility, Reproductive; Pathologic Function
T18	PROC 860 880	control de natalidad
#14	AnnotatorNotes T18	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T19	DISO 1211 1214	VHC
#15	AnnotatorNotes T19	C0019196; Hepatitis C; Disease or Syndrome
T20	PROC 990 1045	test de detección de antígeno superficie de Hepatitis B
#16	AnnotatorNotes T20	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T21	PROC 1047 1052	HbsAg
#17	AnnotatorNotes T21	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T22	PROC 1069 1127	anticuerpos frente al virus de la inmunodeficiencia humana
#18	AnnotatorNotes T22	C3714540; HIV Antibody Measurement; Laboratory Procedure
T23	PROC 1129 1135	Ab VIH
#19	AnnotatorNotes T23	C0019683; HIV Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T24	DISO 1153 1167	comorbilidades
#20	AnnotatorNotes T24	C1275743; Co-morbid conditions; Finding
T25	CHEM 1309 1318	ritonavir
#21	AnnotatorNotes T25	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T26	PROC 1345 1362	terapia antiviral
T27	CHEM 1395 1402	agentes
#22	AnnotatorNotes T27	C0450442; Agent; Chemical Viewed Functionally
T28	DISO 1498 1506	cirrosis
#23	AnnotatorNotes T28	C1623038; Cirrhosis; Disease or Syndrome
T29	ANAT 265 270	renal
#24	AnnotatorNotes T29	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T30	DISO 725 743	cirrhosis hepatica
T31	CHEM 559 568	antiviral
#25	AnnotatorNotes T31	C0003451; Antiviral Agents; Pharmacologic Substance
T32	CHEM 1353 1362	antiviral
#26	AnnotatorNotes T32	C0003451; Antiviral Agents; Pharmacologic Substance
T33	CHEM 143 152	Dasabuvir
#27	AnnotatorNotes T33	C3852512; dasabuvir; Organic Chemical · Pharmacologic Substance
T34	CHEM 110 122	Paritaprevir
#28	AnnotatorNotes T34	C3864824; paritaprevir; Organic Chemical · Pharmacologic Substance
T35	ANAT 735 743	hepatica
#29	AnnotatorNotes T35	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T36	CHEM 1321 1330	dasabuvir
#30	AnnotatorNotes T36	C3852512; dasabuvir; Organic Chemical · Pharmacologic Substance
T37	CHEM 1285 1295	ombitasvir
#31	AnnotatorNotes T37	C3852670; ombitasvir; Organic Chemical · Pharmacologic Substance
T38	DISO 1380 1383	VHC
#32	AnnotatorNotes T38	C0019196; Hepatitis C; Disease or Syndrome
T39	CHEM 1296 1308	paritaprevir
#33	AnnotatorNotes T39	C3864824; paritaprevir; Organic Chemical · Pharmacologic Substance
T40	Date 13 17	2015
T41	Neg_cue 139 142	sin
T42	LIVB 156 163	adultos
#34	AnnotatorNotes T42	C0001675; Adult; Age Group
T43	Duration 178 185	crónica
#35	AnnotatorNotes T43	C0205191; chronic; Temporal Concept
T44	LIVB 193 216	virus de la Hepatitis C
#36	AnnotatorNotes T44	C0220847; hepatitis C virus; Virus
T46	PROC 230 239	genotipos
#37	AnnotatorNotes T46	C1285573; Genotype determination; Laboratory Procedure
T47	Duration 342 349	Cronica
T48	Duration 405 412	crónica
#38	AnnotatorNotes T48	C0205191; chronic; Temporal Concept
T49	LIVB 416 419	VHC
#39	AnnotatorNotes T49	C0220847; hepatitis C virus; Virus
T50	LIVB 486 489	VHC
#40	AnnotatorNotes T50	C0220847; hepatitis C virus; Virus
T51	PROC 494 502	genotipo
#41	AnnotatorNotes T51	C1285573; Genotype determination; Laboratory Procedure
T52	LIVB 514 521	Sujetos
#42	AnnotatorNotes T52	C0681850; Study Subject; Group
T53	Neg_cue 526 531	nunca
T55	Neg_cue 707 710	Sin
T56	LIVB 748 755	Mujeres
#43	AnnotatorNotes T56	C0043210; Woman; Population Group
T58	Duration 780 793	más de 2 años
T59	LIVB 911 930	Mujeres embarazadas
#44	AnnotatorNotes T59	C0033011; Pregnant Women; Population Group
T60	PHYS 949 958	lactancia
#45	AnnotatorNotes T60	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T61	LIVB 1091 1127	virus de la inmunodeficiencia humana
#46	AnnotatorNotes T61	C0019682; HIV; Virus
T62	LIVB 1132 1135	VIH
#47	AnnotatorNotes T62	C0019682; HIV; Virus
T64	LIVB 1232 1238	sujeto
#48	AnnotatorNotes T64	C0681850; Study Subject; Group
T68	Date 1479 1485	actual
T69	Date 1488 1494	pasada
T45	PHYS 919 930	embarazadas
#49	AnnotatorNotes T45	C0032961; Pregnancy; Organism Function
T54	CHEM 1011 1045	antígeno superficie de Hepatitis B
#50	AnnotatorNotes T54	C0019168; Hepatitis B Surface Antigen; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T57	Neg_cue 1239 1241	no
T63	PHYS 624 643	filtrado glomerular
#51	AnnotatorNotes T63	C0232809; Glomerular filtration; Organ or Tissue Function; Laboratory Procedure
T65	CHEM 1395 1402;1430 1446	agentes en investigación
#52	AnnotatorNotes T65	C0013230; Investigational New Drugs; Pharmacologic Substance
T66	ANAT 633 643	glomerular
#53	AnnotatorNotes T66	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
T67	PROC 800 825	estériles quirúrgicamente
#54	AnnotatorNotes T67	C0015787; Female Sterilization; Therapeutic or Preventive Procedure
A1	Assertion T33 Negated
A2	Population_data T42 Age
A3	Assertion T12 Negated
A4	Assertion T30 Negated
A5	Assertion T37 Negated
A6	Assertion T39 Negated
A7	Assertion T25 Negated
A8	Assertion T36 Negated
A9	Assertion T31 Negated
A10	Status T26 History_of
A11	Status T32 History_of
A12	Status T12 History_of
A13	Status T31 History_of
A14	Status T67 History_of
A15	Status T65 History_of
A16	Status T27 History_of
A17	Status T28 History_of
#55	AnnotatorNotes T47	C0205191; chronic; Temporal Concept
#56	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity
#57	AnnotatorNotes T14	C0019196; Hepatitis C; Disease or Syndrome
#58	AnnotatorNotes T8	C0524910; Hepatitis C, Chronic; Disease or Syndrome
#59	AnnotatorNotes T9	C0524910; Hepatitis C, Chronic; Disease or Syndrome
#60	AnnotatorNotes T30	C0023890; Liver Cirrhosis; Disease or Syndrome
#61	AnnotatorNotes T26	C0280274; Antiviral Therapy; Therapeutic or Preventive Procedure 
#62	AnnotatorNotes T68	C0521116; Current (present time); Temporal Concept 
#63	AnnotatorNotes T69	C1444637; In the past; Temporal Concept
R1	Combined_with Arg1:T7 Arg2:T34	
R2	Combined_with Arg1:T34 Arg2:T3	
R3	Negation Arg1:T41 Arg2:T33	
R4	Combined_with Arg1:T3 Arg2:T33	
R5	Experiences Arg1:T42 Arg2:T7	
R6	Experiences Arg1:T42 Arg2:T4	
R7	Experiences Arg1:T42 Arg2:T1	
R8	Experiences Arg1:T42 Arg2:T46	
R9	Experiences Arg1:T42 Arg2:T5	
R10	Experiences Arg1:T42 Arg2:T6	
T70	Quantifier_or_Qualifier 271 276	grave
#64	AnnotatorNotes T70	C1547227; Severe - Severity of Illness Code; Intellectual Product
R11	Location_of Arg1:T29 Arg2:T5	
R12	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T70	
R13	Has_Duration_or_Interval Arg1:T4 Arg2:T43	
R14	Has_Duration_or_Interval Arg1:T1 Arg2:T43	
R15	Causes Arg1:T44 Arg2:T4	
R16	Causes Arg1:T44 Arg2:T1	
T71	Quantifier_or_Qualifier 230 246	genotipos 1a o 4
R17	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T71	
R18	Has_Duration_or_Interval Arg1:T8 Arg2:T47	
R19	Has_Duration_or_Interval Arg1:T9 Arg2:T48	
R20	Causes Arg1:T49 Arg2:T9	
T72	Quantifier_or_Qualifier 494 509	genotipo 1a o 4
R21	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T72	
R22	Causes Arg1:T50 Arg2:T10	
T73	PROC 456 465	selección
#65	AnnotatorNotes T73	C0242802; Patient Selection; Research Activity
R23	Overlap Arg1:T10 Arg2:T73	
R24	Experiences Arg1:T52 Arg2:T12	
R25	Used_for Arg1:T31 Arg2:T12	
R26	Negation Arg1:T53 Arg2:T12	
R27	Negation Arg1:T53 Arg2:T31	
R28	Experiences Arg1:T52 Arg2:T14	
R29	Location_of Arg1:T66 Arg2:T63	
R30	Location_of Arg1:T66 Arg2:T15	
R31	Location_of Arg1:T66 Arg2:T16	
T74	Result_or_Value 651 668	<30 ml/min/1,73m2
R36	Has_Result_or_Value Arg1:T16 Arg2:T74	
R37	Has_Result_or_Value Arg1:T15 Arg2:T74	
R38	Negation Arg1:T55 Arg2:T30	
R39	Location_of Arg1:T35 Arg2:T30	
R40	Experiences Arg1:T56 Arg2:T11	
R41	Has_Duration_or_Interval Arg1:T11 Arg2:T58	
R42	Experiences Arg1:T56 Arg2:T17	
R43	Experiences Arg1:T56 Arg2:T67	
R44	Before Arg1:T67 Arg2:T17	
R45	Experiences Arg1:T56 Arg2:T18	
R46	Experiences Arg1:T59 Arg2:T45	
R47	Experiences Arg1:T59 Arg2:T60	
T75	Result_or_Value 963 981	Resultado positivo
#66	AnnotatorNotes T75	C1446409; Positive; Finding
R48	Has_Result_or_Value Arg1:T20 Arg2:T75	
R49	Has_Result_or_Value Arg1:T21 Arg2:T75	
T76	Quantifier_or_Qualifier 1168 1195	clínicamente significativas
R50	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T76	
T77	Observation 1141 1150	Anomalías
#67	AnnotatorNotes T77	C1704258; Abnormality; Finding
R51	Experiences Arg1:T64 Arg2:T77	
R52	Experiences Arg1:T64 Arg2:T24	
R53	Experiences Arg1:T64 Arg2:T19	
R54	Overlap Arg1:T24 Arg2:T19	
R55	Overlap Arg1:T77 Arg2:T19	
T78	Observation 1248 1274	participar en este estudio
#68	AnnotatorNotes T78	C1278516; Patient participation status; Finding (?)
A18	Assertion T78 Negated
R56	Negation Arg1:T57 Arg2:T78	
R58	Before Arg1:T77 Arg2:T78	
R59	Before Arg1:T24 Arg2:T78	
R60	Negation Arg1:T57 Arg2:T37	
R61	Negation Arg1:T57 Arg2:T39	
R62	Negation Arg1:T57 Arg2:T25	
R63	Negation Arg1:T57 Arg2:T36	
R64	Before Arg1:T77 Arg2:T37	
R65	Before Arg1:T77 Arg2:T39	
R66	Before Arg1:T77 Arg2:T25	
R67	Before Arg1:T77 Arg2:T36	
R68	Combined_with Arg1:T37 Arg2:T39	
R69	Combined_with Arg1:T39 Arg2:T25	
R70	Combined_with Arg1:T25 Arg2:T36	
R71	Before Arg1:T24 Arg2:T37	
R72	Before Arg1:T24 Arg2:T39	
R73	Before Arg1:T24 Arg2:T25	
R74	Before Arg1:T24 Arg2:T36	
R75	Experiences Arg1:T64 Arg2:T37	
R76	Used_for Arg1:T32 Arg2:T26	
R77	Used_for Arg1:T27 Arg2:T26	
T79	Quantifier_or_Qualifier 1403 1427	aprobados comercialmente
R78	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T79	
R79	Overlap Arg1:T28 Arg2:T69	
R80	Overlap Arg1:T28 Arg2:T68	
#69	AnnotatorNotes T76	C5209294; Clinical relevance; Intellectual Product
A19	Experiencer T42 Patient
A20	Experiencer T52 Patient
A21	Experiencer T56 Patient
A22	Experiencer T59 Patient
A23	Experiencer T64 Patient
